Prostate-specific antigen (PSA)-based screening for prostate cancer was introduced in the late 1980s and has since contributed substantially to early disease detection and the subsequent decline in age-standardised mortality rates [1]. This evidence concerns the gene KLK3 and prostate carcinoma.